Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD147-CAR T Cells in R/R T-cell Non-Hodgkin's Lymphoma
NCT05013372Phase 1Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CD147 CAR T cells in T-cell non-Hodgkin lymphoma, sponsored by Peking University People's Hospital. Primary endpoints: Maximum Tolerated Dose at 12 months, Dose-Limiting Toxicity at 12 months and 3 more. Status: unknown.
02
Drugs
CD147 CAR T cells
03
Conditions
T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05013372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013372.